My site

(BUSINESS WIRE) -- After three successful decades of redefining, shaping, and informing the pharmaceutical compounding industry standard, Medisca is proud to unveil a new global brand identity and corporate positioning that reflects a journey of growth, diversification, and opportunity. Founded in 1989 as a small business with a handful of employees, Medisca has expanded into a global corporation with strategic partners in education, manufacturing, supply chain, and analytical testing that deliver customized solutions with an unwavering commitment to quality and innovation.

When asked why the company was making the change now, Medisca Founder and President, Antonio Dos Santos, explained: “It was simple – Medisca had reached a pivotal point and we needed to unite our companies and partners under one shared purpose and identity, paving the way for future growth acceleration and opportunity. Thinking, acting, and behaving as a single entity will position us t ... Read more »

MUNICH - Tuesday, 23. August 2022

(BUSINESS WIRE)--Applications open today for exceptional non-profit organisations working in the fields of climate change mitigation and education to join Personio Foundation’s Impact Portfolio. Successful organisations will receive unrestricted multi-year grants, strategic support and access to Personio HR management software for free. Additionally, grantees have the opportunity to help co-create our HR Accelerator and a shared community with other impact portfolio partners.

Personio Foundation’s mission is to support forward-thinking, innovative organisations working on climate action and education through its Impact Portfolio and HR Accelerator. Since launching in December, the Foundation now supports eight NGOs through its Impact Portfolio, while its HR Accelerator has begun producing content to help non-profit organisations upskill in HR.

Hanno Renner, Co-founder of Personio and Chairman of the Foundation, sa ... Read more »

Wilmington, DE
Over $200 million of direct additional value provided to Delaware taxpayers in first 3 years of operations

October 3rd, 2022, will mark GT USA Wilmington’s (GTW) fourth year into a 50-year concession agreement managing and operating the Port of Wilmington in Delaware. To say there have been a few unforeseen challenges thrown its way is an understatement. Indeed, who could have foreseen that within months after the ceremonial handover the world would be amid a global pandemic.

Throughout the challenging times GTW diligently pursued new business through its global network and built new facilities to enhance customer services. It has ensured that cargos of fresh food and other necessities moved quickly, without disruption, onto supermarket shelves. Throughout the entire pandemic and beyond, the Port has remained fully functioning, with no delays, retaining all employees throughout.

2022 has seen a robust increase in throughput. The Por ... Read more »

OSAKA, Japan & CAMBRIDGE, Mass. - Tuesday, 23. August 2022

Indonesia National Agency for Drug and Food Control, BPOM, Approved QDENGA (TAK-003) for Use in Individuals Six Years to 45 Years of Age1
QDENGA is the Only Dengue Vaccine Approved in Indonesia for Use in Individuals Without Need for Pre-vaccination Testing
Indonesia Approval Marks the First for QDENGA, Takeda’s First Marketed Vaccine Outside of Japan
 

(BUSINESS WIRE) -- Takeda (TSE:4502/NYSE:TAK) today announced the company’s dengue vaccine, QDENGA® (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003), was approved by the Indonesia National Agency for Drug and Food Control, Badan Pengawas Obat dan Makanan (BPOM), for the prevention of dengue disease caused by any serotype in individuals six years to 45 years of age. The use of QDENGA should be in accordance with official recommendations. QDENGA is the only dengue vaccine approved in Indonesia for use in indivi ... Read more »

(BUSINESS WIRE) -- Miracor Medical SA (Miracor Medical) has announced the approval of an Investigational Device Exemption (IDE) from the FDA, enabling the company to initiate a pivotal study with its Pressure-controlled intermittent Coronary Sinus Occlusion (PiCSO) technology. The PiCSO-AMI-II multicenter, randomized trial will enroll 300 patients with anterior ST-segment Elevation Myocardial Infarction (STEMI) presenting with TIMI flow 0, 1, and 2 within 12 hours of symptom onset. The primary efficacy endpoint of the study will be infarct size measured by cardiac magnetic resonance imaging (CMR) at 5 days. The primary safety endpoint is a performance goal for device and procedure related adverse events at 30 days. Major adverse cardiac events and heart failure endpoints will be captured acutely and for up to 3 years.

PiCSO-AMI-II will be the second major randomized trial to evaluate the role of PiCSO in improving coronary microvascular function and reducing infarct size in ... Read more »

Cairo, Egypt - Tuesday, 23. August 2022

Hyundai, Samsung, Technip Energies, and Tecnicas Reunidas competing to construct chemicals complex in the Suez Canal Economic Zone

Anchorage Investments, which develops, implements, and operates industrial projects in the chemicals and blue hydrogen sectors, has shortlisted four international contractors in the second phase of the EPC (engineering, procurement, and construction) tender for the Anchor Benitoite project.

The USD 2 billion project comprises a chemicals complex that will be built in the industrial zone of the General Authority for the Suez Canal Economic Zone (SCZONE) in Egypt.

The four shortlisted companies are HYUNDAI Engineering & Construction Co., Ltd. (HDEC), SAMSUNG Engineering Co., Ltd. of South Korea, TECHNIP ENERGIES, S.p.A. of Italy, and TECNICAS REUNIDAS, S.A. of Spain. Each company is experienced in the applications of propane dehydrogenation (PDH) and polypropylene. 

Authorities must consider every consumer segment and strive to ensure that safer smoking alternatives are less expensive than tobacco cigarettes

(BUSINESS WIRE) -- RELX International, a responsible multinational electronic cigarette company, is cautioning authorities against increasing the customs duties levied on e-cigarette products.

A move on this would make these safer smoking alternatives as expensive as tobacco cigarettes. Increased taxation could spur the growth of black-market activities, put consumers’ health at risk, reduce government tax income, and make the city/country a less attractive option for investment and entrepreneurship.

In recent years scientific research, as well as national healthcare providers, including the United Kingdom’s National Health Service (NHS), have recognised e-cigarette products as a safer alternative to tobacco cigarettes, and have highlighted their use as a ‘stop smoking aid’[1]. In contrast, th ... Read more »

ST. GALLEN, Switzerland & STAMFORD, Conn. - Friday, 19. August 2022

Kapruvia® (difelikefalin) is the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients

Therapy recently approved in Canada under the brand name KORSUVA®

Regulatory decisions in Australia and Singapore expected by the end of 2022

(BUSINESS WIRE) --Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Products (Swissmedic). Kapruvia® will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients. Swissmedic approval for Kapruvia® follows approvals by the U.S. Food and Drug Administration, by the European Medicines Agency, by the UK Medic ... Read more »